Skip to main content

Advertisement

SpringerLink
Log in

Neuro-oncology

A step towards clinical blood biomarkers of glioblastoma

  • News & Views
  • Published:

From Nature Reviews Neurology

View current issue Sign up to alerts

Glioblastoma is the most common primary brain tumour in adults, but—unlike many other cancers—no blood-based biomarkers are available for differential diagnosis, estimation of prognosis or monitoring of treatment response in glioblastoma. New research has detected three proteins with potential clinical value in the blood of patients with glioblastoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ilhan-Mutlu, A., Wagner, L. & Preusser, M. Circulating biomarkers of CNS tumors: an update. Biomark. Med. 7, 267–285 (2013).

    Article  CAS  Google Scholar 

  2. Gallego Perez-Larraya, J. et al. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma. Cancer http://dx.doi.org/10.1002/cncr.28949.

  3. Ilhan-Mutlu, A. et al. Exploratory investigation of eight circulating plasma markers in brain tumor patients. Neurosurg. Rev. 36, 45–55 (2013).

    Article  Google Scholar 

  4. Brommeland, T., Rosengren, L., Fridlund, S., Hennig, R. & Isaksen, V. Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol. Scand. 116, 380–384 (2007).

    Article  CAS  Google Scholar 

  5. Jung, C. S. et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 130, 3336–3341 (2007).

    Article  CAS  Google Scholar 

  6. Muller, C. et al. Hematogenous dissemination of glioblastoma multiforme. Sci. Transl. Med. 6, 247ra101 (2014).

    Article  Google Scholar 

  7. Bernardi, D. et al. Serum YKL-40 following resection for cerebral glioblastoma. J. Neurooncol. 107, 299–305 (2012).

    Article  CAS  Google Scholar 

  8. Prakash, M. et al. Diverse pathological implications of YKL-40: answers may lie in 'outside-in' signaling. Cell. Signal. 25, 1567–1573 (2013).

    Article  CAS  Google Scholar 

  9. Baxter, R. C. IGF binding proteins in cancer: mechanistic and clinical insights. Nat. Rev. Cancer 14, 329–341 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine I, Comprehensive Cancer Centre Vienna, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, 1090, Austria

    Matthias Preusser

Authors
  1. Matthias Preusser
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Preusser.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Preusser, M. A step towards clinical blood biomarkers of glioblastoma. Nat Rev Neurol 10, 681–682 (2014). https://doi.org/10.1038/nrneurol.2014.208

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2014.208

  • Springer Nature Limited

This article is cited by

Search

Navigation